| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Screening and prostate-cancer mortality in a randomized European study.
|
N Engl J Med
|
2009
|
35.94
|
|
2
|
Prostate-cancer mortality at 11 years of follow-up.
|
N Engl J Med
|
2012
|
16.91
|
|
3
|
Quality-of-life effects of prostate-specific antigen screening.
|
N Engl J Med
|
2012
|
7.21
|
|
4
|
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.
|
Eur Urol
|
2010
|
4.45
|
|
5
|
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
|
Eur Urol
|
2009
|
3.42
|
|
6
|
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
|
Eur Urol
|
2013
|
3.34
|
|
7
|
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.
|
Eur Urol
|
2012
|
3.30
|
|
8
|
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
|
Clin Cancer Res
|
2010
|
2.87
|
|
9
|
Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.
|
Radiology
|
2013
|
2.47
|
|
10
|
A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy.
|
Eur Urol
|
2009
|
2.47
|
|
11
|
Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.
|
BJU Int
|
2011
|
2.41
|
|
12
|
Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.
|
Urology
|
2009
|
2.16
|
|
13
|
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.
|
Int J Cancer
|
2010
|
2.15
|
|
14
|
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
|
Eur Urol
|
2011
|
1.87
|
|
15
|
Endoluminal occlusion of the inferior vena cava in renal cell carcinoma with retro- or suprahepatic caval thrombus.
|
BJU Int
|
2006
|
1.71
|
|
16
|
Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology.
|
Prostate
|
2009
|
1.66
|
|
17
|
Results of endoluminal occlusion of the inferior vena cava during radical nephrectomy and thrombectomy.
|
Eur Urol
|
2008
|
1.55
|
|
18
|
Seasonality of serum prostate-specific antigen levels: a population-based study.
|
Eur Urol
|
2006
|
1.48
|
|
19
|
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2011
|
1.42
|
|
20
|
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
|
BJU Int
|
2011
|
1.37
|
|
21
|
Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract.
|
BJU Int
|
2009
|
1.29
|
|
22
|
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?
|
J Magn Reson Imaging
|
2012
|
1.18
|
|
23
|
Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading.
|
Urology
|
2011
|
1.15
|
|
24
|
Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology.
|
Prostate
|
2009
|
1.11
|
|
25
|
Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography.
|
Curr Opin Urol
|
2009
|
1.06
|
|
26
|
Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53.
|
Arch Pathol Lab Med
|
2007
|
1.06
|
|
27
|
Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma.
|
Histopathology
|
2010
|
1.05
|
|
28
|
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
|
BMC Cancer
|
2010
|
1.03
|
|
29
|
Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings.
|
Eur Radiol
|
2008
|
1.02
|
|
30
|
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
|
World J Urol
|
2011
|
1.00
|
|
31
|
Race affects access to nephrectomy but not survival in renal cell carcinoma.
|
BJU Int
|
2008
|
0.98
|
|
32
|
Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature.
|
Cancer Treat Rev
|
2011
|
0.98
|
|
33
|
Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages.
|
BJU Int
|
2013
|
0.97
|
|
34
|
A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy.
|
BJU Int
|
2012
|
0.97
|
|
35
|
Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.
|
BJU Int
|
2011
|
0.96
|
|
36
|
Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results.
|
Int J Comput Assist Radiol Surg
|
2008
|
0.94
|
|
37
|
Renal cell carcinoma associated with tumor thrombus in the inferior vena cava: surgical strategies.
|
Ann Vasc Surg
|
2005
|
0.94
|
|
38
|
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2012
|
0.94
|
|
39
|
Multimodality magnetic resonance imaging of prostate cancer.
|
J Endourol
|
2010
|
0.93
|
|
40
|
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project.
|
BJU Int
|
2014
|
0.93
|
|
41
|
Focal laser ablation of prostate cancer: definition, needs, and future.
|
Adv Urol
|
2012
|
0.92
|
|
42
|
Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
|
Urology
|
2011
|
0.92
|
|
43
|
The efficacy of intrathecal morphine with or without clonidine for postoperative analgesia after radical prostatectomy.
|
Anesth Analg
|
2009
|
0.91
|
|
44
|
The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer.
|
World J Urol
|
2014
|
0.91
|
|
45
|
[Gastric or duodenal metastases from clear cell renal cell carcinoma. Report of two cases and review of the literature].
|
Prog Urol
|
2007
|
0.89
|
|
46
|
Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma.
|
BJU Int
|
2008
|
0.89
|
|
47
|
Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
|
Mol Cancer Res
|
2011
|
0.88
|
|
48
|
Focal laser interstitial thermotherapy (LITT) at 980 nm for prostate cancer: treatment feasibility in Dunning R3327-AT2 rat prostate tumour.
|
BJU Int
|
2011
|
0.87
|
|
49
|
MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma.
|
Am J Surg Pathol
|
2003
|
0.86
|
|
50
|
Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway.
|
Urol Oncol
|
2013
|
0.84
|
|
51
|
Testicular natural killer T-cell lymphoma.
|
Int J Urol
|
2005
|
0.84
|
|
52
|
Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance.
|
J Urol
|
2008
|
0.83
|
|
53
|
Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series.
|
BJU Int
|
2011
|
0.82
|
|
54
|
Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry.
|
Appl Immunohistochem Mol Morphol
|
2012
|
0.82
|
|
55
|
How are we going to train a generation of radiologists (and urologists) to read prostate MRI?
|
Curr Opin Urol
|
2015
|
0.81
|
|
56
|
External validation of outcome prediction model for ureteral/renal calculi.
|
J Urol
|
2006
|
0.81
|
|
57
|
A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses.
|
BJU Int
|
2009
|
0.81
|
|
58
|
[Should scrotal ultrasound be discouraged in cases of suspected spermatic cord torsion?].
|
Prog Urol
|
2003
|
0.80
|
|
59
|
Polytetrafluoroethylene expanded prosthesis as replacement of the inferior vena cava in renal cell carcinoma with caval thrombus.
|
Int J Urol
|
2014
|
0.80
|
|
60
|
The use of partial nephrectomy: results from a contemporary national prospective multicenter study.
|
World J Urol
|
2014
|
0.80
|
|
61
|
Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.
|
J Urol
|
2013
|
0.79
|
|
62
|
[Prostatic cancers].
|
Prog Urol
|
2007
|
0.78
|
|
63
|
Prostate cancer computer-assisted diagnosis software using dynamic contrast-enhanced MRI.
|
Conf Proc IEEE Eng Med Biol Soc
|
2007
|
0.78
|
|
64
|
[Ureteric and bladder involvement of deep pelvic endometriosis. Value of multidisciplinary surgical management].
|
Prog Urol
|
2006
|
0.78
|
|
65
|
Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study.
|
World J Urol
|
2013
|
0.78
|
|
66
|
Understanding the pathological implications of MRI: application to focal therapy planning.
|
Curr Opin Urol
|
2015
|
0.76
|
|
67
|
MRI and surveillance.
|
Curr Opin Urol
|
2012
|
0.76
|
|
68
|
[Cost and efficacy of treatment strategies in localized prostatic cancer: feasibility study in the general population].
|
Prog Urol
|
2003
|
0.76
|
|
69
|
[Cystic prostate cancer: a clinical entity of ductal carcinoma].
|
Prog Urol
|
2004
|
0.76
|
|
70
|
How accurately can MRI detect indolent disease?
|
Curr Opin Urol
|
2014
|
0.76
|
|
71
|
ESUR prostate MR guidelines. Author reply.
|
Eur Radiol
|
2013
|
0.76
|
|
72
|
[Long-term oncological results after conservative surgery for unifocal renal cancer].
|
Prog Urol
|
2003
|
0.75
|
|
73
|
[The prostate: how to treat this symbol of male vulnerability? An Association Française d'Urologie (AFU)-IPSOS qualitative survey].
|
Prog Urol
|
2007
|
0.75
|
|
74
|
[Urachal cancers].
|
Bull Cancer
|
2013
|
0.75
|
|
75
|
[Update on screening, diagnosis and treatment of cancer of the prostate].
|
Bull Cancer
|
2002
|
0.75
|
|
76
|
[Prostate cancer screening].
|
Prog Urol
|
2003
|
0.75
|
|
77
|
[Prostate cancer screening].
|
Prog Urol
|
2003
|
0.75
|
|
78
|
Celiac axis and superior mesenteric artery: danger zone for left nephrectomy.
|
J Endourol
|
2008
|
0.75
|
|
79
|
[Indications for pelvic lymphadenectomy in clinically localized prostate cancer].
|
Prog Urol
|
2004
|
0.75
|
|
80
|
Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
|
Urology
|
2009
|
0.75
|
|
81
|
[Place of contrast imaging in prostate cancer detection].
|
Prog Urol
|
2006
|
0.75
|
|
82
|
[Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
|
Bull Cancer
|
2006
|
0.75
|
|
83
|
[Molecular forms of PSA].
|
Prog Urol
|
2007
|
0.75
|
|
84
|
[Prostatic cancer].
|
Prog Urol
|
2004
|
0.75
|
|
85
|
[The epidemiology of prostate cancer].
|
Rev Prat
|
2003
|
0.75
|
|
86
|
[The outbreak of focal therapy for localized prostate cancer management].
|
Rev Prat
|
2013
|
0.75
|
|
87
|
[CAT Scan in hormone-independent prostate cancer].
|
Prog Urol
|
2002
|
0.75
|
|
88
|
[Photodynamic therapy and urothelial carcinoma].
|
Bull Cancer
|
2011
|
0.75
|
|
89
|
[Primary neuroectodermal tumour of the kidney invading the wall of the inferior vena cava. Surgical strategy].
|
Prog Urol
|
2004
|
0.75
|